Methods for inhibiting muscle atrophy

• US 10,137,136 B2
• Filed: 02/23/2016
• Issued: 11/27/2018
• Est. Priority Date: 06/06/2011
• Status: Active Grant

• Current Assignee: US Department of Veterans Affairs (Government of the United States of America), The United States of America as represented by the Department of Veterans Affairs, Office of the Gen
• Original Assignee: The United States of America as represented by the Department of Veterans Affairs, Office of the Gen, University of Iowa Research Foundation
• Inventors: Adams, Christopher M., Kunkel, Steven D., Welsh, Michael
• Primary Examiner(s): Heyer, Dennis
• Application Number:
  US15/051,246
• Publication Number:
  US 20160243132A1
• Time in Patent Office: 1,008 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• CPC Class Codes: A61K 31/382 having six-membered rings, e.g. thioxanthenes thiothixene A61K31/496
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• CPC Class Codes: A61K 31/435 having six-membered rings with one nitrogen as the only ring hetero atom
• CPC Class Codes: A61K 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/4365 the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/4375 the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• CPC Class Codes: A61K 31/438 The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• CPC Class Codes: A61K 31/4706 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 : not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/58 : containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 : Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 21/06 : Anabolic agents androgens A61P5/26
• CPC Class Codes: A61P 3/08 : for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12Q 1/6809 : Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 2600/136 : Screening for pharmacological compounds
• CPC Class Codes: G01N 2800/10 : Musculoskeletal or connective tissue disorders
• CPC Class Codes: G01N 2800/52 : Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5023 : on expression patterns

Abstract

In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims

1. A method for enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in an animal identified or having been identified to be in need of enhanced muscle formation, increased muscle mass, or reduced muscle atrophy, the method comprising administering to the animal an effective amount of ursolic acid or a salt, solvate, or polymorph thereof, thereby enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in the animal, wherein said animal:

(a) is a primate that has not been diagnosed with a need for treatment of diabetes;

or

(b) is selected from the group consisting of a domesticated fish, domesticated crustacean, domesticated mollusk, poultry, rabbit, dog, cat, guinea pig, and livestock.

2. The method according to claim 1, wherein the animal is a non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, domesticated fish, or poultry.

3. The method according to claim 1, comprising administering the ursolic acid, salt, solvate, or polymorph thereof orally, in a composition that comprises a preservative.

4. The method according to claim 1, wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a food, nutraceutical, energy bar, energy drink, supplement, capsule, cachet, or tablet.

5. The method according to claim 1, comprising administering to the animal 0.1 to 250 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

6. The method according to claim 1, comprising administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

7. The method according claim 1, comprising administering to the animal greater than 50 mg of the ursolic acid, salt, solvate, or polymorph thereof per day.

8. The method according to claim 1, wherein the animal has not been diagnosed with a need for treatment of diabetes or cancer.

9. The method according to claim 8, for enhancing muscle formation.

10. The method according to claim 8, for increasing muscle mass.

11. The method according to claim 8, for reducing muscle atrophy.

12. The method according to claim 8, comprising orally administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

13. The method according to claim 12, wherein the animal is a horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, domesticated fish, or poultry.

14. The method according to claim 1, wherein the primate is a human that has been identified to be in need of enhanced muscle formation, increased muscle mass, or reduced muscle atrophy for aesthetic or self-improvement purposes.

15. The method according to claim 14, wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a nutraceutical, energy bar, energy drink, or supplement.

16. The method according to claim 14, wherein the human does not have diabetes or cancer.

17. The method according to claim 1, wherein the animal is selected from the group consisting of a dog, cat, domesticated fish, poultry, and livestock.

18. The method according to claim 17, wherein the animal is domesticated fish, or livestock selected from a cow, horse, and pig.

19. The method according to claim 17, comprising orally administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

20. The method according to claim 19, wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a composition that is administered to the animal, and wherein the composition contains greater than 200 mg of the ursolic acid, salt, solvate, or polymorph thereof.